Recent Federal Circuit case law on section 112(a) has raised serious doubts over the enforceability of US genus claims, leaving life sciences rights holders in a quandary.
4 Feb
2021
SCOTUS’ denial of certiorari in Idenix v Gilead poses especially difficult IP questions for universities and small biotechs
